While “interesting,” the “subgroups with ‘significant benefit’ don’t necessarily make sense,” said late-breaking clinical trial session discussant Larry Allen of the University of Colorado.
CU Anschutz
Academic Office One
12631 East 17th Avenue
8601
Aurora, CO 80045